In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...

Novartis has agreed to partner on developing additional molecular glue degraders (MGDs) for immune-mediated diseases, in an expanded collaboration that could generate more than $5.7 billion for the ...

AI is reshaping work, but eliminating entry-level jobs is short-sighted. These roles are crucial for developing future ...

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to US$5.7 billion on Monday to develop drugs for immune-mediated diseases.

Monte Rosa stock soars 38% after a $5.7B Novartis partnership to develop AI-powered degraders for immune diseases. Read more ...

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics agreed to an up to $5.7 billion licensing deal to develop ...

Get the latest healthcare market updates, stock performance, and key pharma news, including Trump’s drug price push and major ...

Novartis (Switzerland) is a global pharmaceutical leader and one of the pioneers in advancing radioligand therapy (RLT). The ...

We need not consider whether Novartis would suffer irreparable injury because it cannot demonstrate ‘certainty of success on ...

The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 ...

The global chronic myelomonocytic leukemia (CMML) market is set for significant growth due to rising CMML cases, advanced targeted therapies, and increased disease awareness. Recognized as a rare ...